文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

再生障碍性贫血免疫抑制治疗下的克隆性造血模式

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.
PubMed 文献 · Leukemia · 2026-09-03

该研究分析了371例接受免疫抑制治疗的再生障碍性贫血患者,其中237例进行连续靶向测序。基线时22%检出体细胞突变,治疗后升至41%,ASXL1等高危克隆持续扩增而BCOR、PIGA等有利克隆缩小或稳定,提示需长期分子监测。

要点

  • 免疫抑制治疗后体细胞突变检出率从22%升至41%,需长期分子监测。
  • ASXL1等高危突变持续扩增,BCOR和PIGA等有利克隆缩小或稳定。
  • 年龄较大与突变负荷较高相关,疾病严重程度与突变增加幅度相关。

核心结论

  • 免疫抑制治疗后再障患者克隆性造血模式呈动态变化,高危克隆扩增而有利克隆稳定或缩小,支持长期分子监测。

研究设计与样本

  • 分析371例接受免疫抑制治疗的再生障碍性贫血患者,全部行PNH检测,357例可评估细胞遗传学,237例接受连续靶向测序。

主要发现

  • 237例中基线检出体细胞突变53例(22%),免疫抑制治疗后增至97例(41%)。
  • ASXL1等高危突变持续扩增,BCOR和PIGA等有利克隆常缩小或保持稳定。
  • 年龄较大与突变负荷较重相关,疾病严重程度与突变增加幅度较大相关。
  • 357例中细胞遗传学异常基线18例(5%),治疗后升至37例(10%)。
  • PNH克隆基线存在20%,随访中相对稳定,15例进展为PNH综合征,6例演化为髓系肿瘤。

临床怎么用

  • 对接受免疫抑制治疗的再障患者应进行长期分子监测,关注高危克隆扩增及PNH克隆演变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aplastic anemia (AA) is an immune-mediated bone marrow failure disorder with 15-20% risk of clonal evolution. We analyzed 371 patients with AA receiving immunosuppressive therapy (IST). All patients underwent PNH testing and 357 evaluable for cytogenetic analysis. Two hundred and thirty-seven received serial targeted sequencing. Clonal characteristics were compared before and after IST across age, disease severity, and hematological response. Among the 237 patients, somatic mutations were detected in 53 patients (22%) at baseline and 97 (41%) after IST. Distinct patterns of mutational dynamics were observed under IST, with newly acquired mutations defined as Pattern 2 being most common. High-risk mutations such as ASXL1 expanded persistently, whereas favorable clones like BCOR and PIGA often contracted or remained stable. Older age was associated with heavier mutational burden, and disease severity was associated with greater increase in mutations. Cytogenetic abnormalities were observed in 18 of 357 patients (5%) and rose to 37 (10%) post-treatment. PNH clones were present in 20% of patients at baseline and remained relatively stable during follow-up, 15 patients progressed to PNH syndrome. Six patients evolved to myeloid neoplasms, including myelodysplastic syndromes and chronic myelomonocytic leukemia. These findings highlight the importance of long-term molecular surveillance (ClinicalTrials.gov number, NCT04645199).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Tian L, Zhang L, Li R, et al. Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy. Leukemia. 2026. PMID: 42693160. doi:10.1038/s41375-026-03048-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。